FDA Warning Letter Novo Nordisk Reveals Serious...

By João L. Carapinha

March 11, 2026

The U.S. Food and Drug Administration (FDA) issued the FDA Warning Letter Novo Nordisk
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Rapid Genetic Testing Mitigates Gentamicin-Induced Hearing Loss in Neonates
Urgent Call for Enhanced Precision Oncology Access in Europe
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
EMA’s mCombriax Vaccine Recommendation
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 T...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Administrative Court Error Complicates Infarmed Vaccine Data Transparency
Enhancing Safety and Performance: The Role of EU Medical Device Panels
Genotype ECG Prediction